Croteau SE, Luo HY, Lehmann LE, Chui DHK, Neufeld EJ. Novel dominant β-thalassemia: Hb Boston-Kuwait [codon 139/140(+T)].
Pediatr Blood Cancer 2013;
60:E131-E134. [PMID:
23776097 DOI:
10.1002/pbc.24611]
[Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2013] [Accepted: 04/30/2013] [Indexed: 01/19/2023]
Abstract
Dominant β-thalassemias exhibit a hybrid phenotype of unstable hemoglobin and ineffective erythropoiesis. Most arise from heterozygous β-globin gene mutations in exons 3 or 2 and present in adulthood as thalassemia intermedia. We report a novel, de novo β-globin mutation presenting in a toddler with features of thalassemia major and chromaturia. Hemoglobin Boston-Kuwait is an elongated β-chain variant (163 amino acids) that results from a frameshift mutation caused by a thymidine insertion in codons 139/140. Hematopoietic stem cell transplant provided a successful alternative therapy for this severe form of dominant β-thalassemia.
Collapse